Previously, we and others demonstrated that acquired resistance in BRAF-altered gliomas occurs through co-mutations that preserve ERK signaling overactivity.9,12 Here, we investigate adaptive resistance at a protein level in human tissue samples, confirming ERK-dependence upon resistance. The gene discussed is BRAF; the disease is central nervous system cancer.